Gefurulimab · Klygefa

Antibody-derived scaffold

Also known as ALXN1720

Phase 3underway

Evidence outlook · registrational

Generalized Myasthenia Gravis: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2026-12-15.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Generalized Myasthenia Gravis
NCT06607627 · Alexion Pharmaceuticals, Inc.
2024-11-13 – 2029-01-23 · Generalized Myasthenia Gravis, gMG
What this study did
NCT05556096 · Alexion Pharmaceuticals, Inc.
2022-11-21 – 2027-08-31 · Generalized Myasthenia Gravis
What this study did
Phase 1 (4)
Other / comorbidity
NCT06677138 · Alexion Pharmaceuticals, Inc.
2024-10-28 – 2025-03-19 · Healthy
What this study did
NCT06208488 · Alexion Pharmaceuticals, Inc.
2023-11-22 – 2024-09-28 · Healthy Adult Participants
What this study did
NCT05314231 · Alexion Pharmaceuticals, Inc.
2022-06-29 – 2023-05-31 · Proteinuria
What this study did
NCT04920370 · Alexion Pharmaceuticals, Inc.
2019-09-04 – 2021-11-16 · Healthy
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Generalized Myasthenia Gravis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Gefurulimab (Klygefa): this drugPhase 3Antibody-derived scaffoldComplement C5not yet gradedNo reviewed efficacy summary in this indication
Avacincaptad Pegol (Izervay)
Approved(overall)
RNA AptamerComplement C5
Reliable signal(overall)
No reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed
Efgartigimod Alfa (Vyvgart)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
InebilizumabApprovedMonoclonal antibodyCD19Reliable signal
NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4)
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ABBV-6628
Phase 1/2(overall)
Antibody fragmentComplement C5
not yet graded(overall)
No reviewed efficacy summary in this indication
AritinerceptPhase 1/2Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Klygefa (Gefurulimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Generalized Myasthenia GravisRecruiting
Est. primary completion 2026-12-15 · NCT06607627 · CT.gov ↗
What to watch

See the full readout calendar ↗